- Home
- OPP vs SGMT Comparison
OPP vs SGMT Comparison
Compare OPP & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPP
- SGMT
- Stock Information
- Founded
- OPP 2010
- SGMT 2006
- Country
- OPP United States
- SGMT United States
- Employees
- OPP N/A
- SGMT N/A
- Industry
- OPP Finance/Investors Services
- SGMT
- Sector
- OPP Finance
- SGMT
- Exchange
- OPP Nasdaq
- SGMT Nasdaq
- Market Cap
- OPP 204.0M
- SGMT 238.7M
- IPO Year
- OPP N/A
- SGMT 2023
- Fundamental
- Price
- OPP $8.11
- SGMT $8.47
- Analyst Decision
- OPP
- SGMT Strong Buy
- Analyst Count
- OPP 0
- SGMT 8
- Target Price
- OPP N/A
- SGMT $26.88
- AVG Volume (30 Days)
- OPP 108.0K
- SGMT 563.6K
- Earning Date
- OPP 01-01-0001
- SGMT 11-13-2025
- Dividend Yield
- OPP 14.41%
- SGMT N/A
- EPS Growth
- OPP N/A
- SGMT N/A
- EPS
- OPP N/A
- SGMT N/A
- Revenue
- OPP N/A
- SGMT N/A
- Revenue This Year
- OPP N/A
- SGMT N/A
- Revenue Next Year
- OPP N/A
- SGMT N/A
- P/E Ratio
- OPP N/A
- SGMT N/A
- Revenue Growth
- OPP N/A
- SGMT N/A
- 52 Week Low
- OPP $7.26
- SGMT $1.73
- 52 Week High
- OPP $8.83
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- OPP 39.85
- SGMT 56.97
- Support Level
- OPP $8.05
- SGMT $7.02
- Resistance Level
- OPP $8.15
- SGMT $8.06
- Average True Range (ATR)
- OPP 0.09
- SGMT 0.64
- MACD
- OPP 0.01
- SGMT -0.00
- Stochastic Oscillator
- OPP 42.62
- SGMT 60.86
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.